Quick Answer
Pacira BioSciences, Inc. reported Revenue (ASC 606) of $726.41 million for fiscal year 2025.
Pacira BioSciences, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $726.41M | +3.6% |
| 2024 | $700.97M | +3.9% |
| 2023 | $674.98M | +1.2% |
| 2022 | $666.82M | +23.1% |
| 2021 | $541.53M | +26.0% |
| 2020 | $429.65M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $179.52M | +6.5% | -0.9% |
| June 30, 2025 | $181.10M | +1.7% | +7.2% |
| March 31, 2025 | $168.92M | +1.1% | +0.2% |
| September 30, 2024 | $168.57M | +2.8% | -5.3% |
| June 30, 2024 | $178.02M | +5.0% | +6.5% |
| March 31, 2024 | $167.12M | +4.2% | +1.9% |
| September 30, 2023 | $163.93M | -2.1% | -3.3% |
| June 30, 2023 | $169.47M | +0.0% | +5.7% |
- Pacira BioSciences, Inc. showed an increase of +3.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2025 period, Pacira BioSciences, Inc.’s revenue (asc 606) has grown by 69.1% (from $429.65 million to $726.41 million).
- The most recent figure is from Pacira BioSciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: